Your browser is no longer supported. Please, upgrade your browser.
Settings
TROV TrovaGene, Inc. daily Stock Chart
TROV [NASD]
TrovaGene, Inc.
Index- P/E- EPS (ttm)-1.09 Insider Own0.30% Shs Outstand30.82M Perf Week-13.94%
Market Cap110.34M Forward P/E- EPS next Y-0.96 Insider Trans0.00% Shs Float26.89M Perf Month-30.89%
Income-27.50M PEG- EPS next Q-0.29 Inst Own35.10% Short Float15.00% Perf Quarter-10.05%
Sales0.30M P/S367.79 EPS this Y-38.30% Inst Trans-0.31% Short Ratio7.49 Perf Half Y-27.24%
Book/sh1.64 P/B2.18 EPS next Y22.00% ROA-46.20% Target Price6.75 Perf Year-63.28%
Cash/sh2.19 P/C1.63 EPS next 5Y- ROE-75.70% 52W Range2.85 - 13.58 Perf YTD-33.70%
Dividend- P/FCF- EPS past 5Y-6.50% ROI- 52W High-73.64% Beta-0.77
Dividend %- Quick Ratio8.30 Sales past 5Y3.30% Gross Margin- 52W Low25.62% ATR0.47
Employees72 Current Ratio8.30 Sales Q/Q0.00% Oper. Margin- RSI (14)30.00 Volatility10.30% 9.50%
OptionableYes Debt/Eq0.34 EPS Q/Q-0.10% Profit Margin- Rel Volume1.02 Prev Close3.58
ShortableYes LT Debt/Eq0.23 EarningsMay 03 AMC Payout- Avg Volume538.48K Price3.58
Recom2.80 SMA20-28.82% SMA50-32.10% SMA200-34.42% Volume0 Change0.00%
Apr-26-16Downgrade Leerink Partners Outperform → Mkt Perform
Apr-25-16Downgrade Piper Jaffray Overweight → Neutral
Apr-25-16Downgrade Cantor Fitzgerald Buy → Hold $9 → $5
Feb-03-16Reiterated Maxim Group Buy $13 → $12
Sep-16-15Initiated Cantor Fitzgerald Buy
Aug-14-15Initiated Leerink Partners Outperform
Apr-20-15Reiterated Maxim Group Buy $10 → $13
Jul-10-14Initiated Maxim Group Buy $10
Nov-13-13Reiterated Aegis Capital Buy $14 → $10
Oct-01-13Reiterated Aegis Capital Buy $14
Jul-16-13Initiated Cantor Fitzgerald Buy $10
Apr-01-13Reiterated Aegis Capital Buy $12 → $14
Dec-12-12Initiated Aegis Capital Buy $12
May-05-16 01:13PM  Lifshitz & Miller Law Firm Announces Investigation of Apigee Corporation, Mentor Graphics Corp., PayPal Holdings Inc., Performance Sports Group, Ltd., PJT Partners, Inc., and Trovagene, Inc. PR Newswire +5.45%
May-03-16 08:15AM  Trovagene Schedules Release of First Quarter 2016 Financial Results and Investor Conference Call PR Newswire -6.02%
Apr-28-16 08:15AM  Trovagene to Present at the 41st Annual Deutsche Bank Healthcare Conference PR Newswire -6.31%
Apr-27-16 05:18PM  TROVAGENE, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits EDGAR Online
09:16AM  What's in Store for TrovaGene (TROV) this Earnings Season? Zacks
Apr-26-16 06:20AM  TrovaGene downgraded by Leerink Partners Briefing.com -8.25%
Apr-25-16 04:48PM  TROVAGENE, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits EDGAR Online -23.83%
08:05AM  Trovagene Appoints Bill Welch as Chief Executive Officer PR Newswire
Apr-15-16 02:02PM  Trovagene Gains 3% On Favorable Mention In Medical Journal
08:17AM  TROVAGENE, INC. Files SEC form 8-K, Other Events
08:15AM  Patient Case Report Demonstrating the Ability of Trovagene's Precision Cancer Monitoring Platform to Determine Early Drug Response Published in Cancer Discovery PR Newswire
Apr-12-16 01:10PM  TrovaGene Inks Strategic Partnership with Stratose, Stock Up
Apr-11-16 10:01AM  TROVAGENE, INC. Files SEC form 8-K, Other Events
08:15AM  Trovagene Enters Into Preferred Provider Agreement with Stratose PPO Network PR Newswire
Apr-08-16 02:25PM  Trovagene, Inc. (TROV): Bridger Management Reports 11% Stake and Goes Activist at Insider Monkey
Apr-07-16 06:58AM  TrovaGene To Present Clinical Data On Its Precision Cancer Monitoring Platform
06:09AM  TROVAGENE, INC. Files SEC form 8-K, Other Events
06:05AM  Clinical Data Featuring Trovagene's Precision Cancer Monitoring Platform to be Presented at the Molecular DX Europe Conference PR Newswire
Mar-30-16 01:41PM  SHAREHOLDER NOTICE: Goldberg Law PC Announces An Investigation of Claims against TrovaGene, Inc. And Advises Investors With Losses To Contact The Firm Business Wire -5.59%
11:26AM  Shareholder Alert: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Trovagene, Inc. - TROV PR Newswire
10:40AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of TrovaGene, Inc. Business Wire
09:48AM  Did a boardroom coup at Trovagene just create a buying opportunity?
Mar-29-16 06:41PM  IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation of Claims against TrovaGene, Inc. And Advises Investors With Losses In Excess of $50,000 To Contact The Firm Business Wire
05:23PM  Harwood Feffer LLP Announces Investigation of Trovagene, Inc. PR Newswire
03:07PM  Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of TrovaGene, Inc. (TROV) PR Newswire
01:23PM  EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Trovagene, Inc. - TROV Business Wire
12:20PM  TrovaGene Plunges on CEO and CFO Dismissal; Files Suit
09:42AM  TROVAGENE, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements and
08:48AM  Trovagene Interim CEO to Host Investor Conference Call at noodls
08:44AM  Trovagene Shareholder (TROV) Alert: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Trovagene, Inc.; Encourages Investors to Contact the Firm PR Newswire
08:36AM  Trovagene Interim CEO to Host Investor Conference Call PR Newswire
08:01AM  TrovaGene Down 40% Following Termination Of CEO, CFO
Mar-28-16 08:26PM  Biotech Trovagene Tumbles After Firing, Suing Its Top Executives
08:26PM  Biotech Trovagene Fires, Sues Its CEO, CFO; Shares Tumble at Bloomberg
07:48PM  Trovagene Terminates the Employment of CEO Antonius Schuh and CFO Stephen Zaniboni for Cause at noodls
07:30PM  Trovagene Terminates the Employment of CEO Antonius Schuh and CFO Stephen Zaniboni for Cause PR Newswire
Mar-24-16 08:18AM  Clinical Study Results Featuring Trovagene's Precision Cancer Monitoring Platform to be Presented at the AACR Annual Meeting 2016 at noodls
08:07AM  TROVAGENE, INC. Files SEC form 8-K, Other Events
08:05AM  Clinical Study Results Featuring Trovagene's Precision Cancer Monitoring Platform to be Presented at the AACR Annual Meeting 2016 PR Newswire
Mar-21-16 01:25PM  Why Healthcare Investors Should Forget about Drug Companies and Focus on Medical Device Companies Accesswire
Mar-16-16 01:04PM  TROVAGENE, INC. Financials
Mar-11-16 12:40PM  Edited Transcript of TROV earnings conference call or presentation 10-Mar-16 10:00pm GMT -10.74%
09:20AM  TrovaGene (TROV) Falls on Wider-than-Expected Q4 Loss
Mar-10-16 11:40PM  /C O R R E C T I O N -- Trovagene, Inc./ PR Newswire -8.89%
06:17PM  Trovagene reports 4Q loss
05:03PM  TROVAGENE, INC. Files SEC form 8-K, Results of Operations and Financial Condition
04:14PM  TROVAGENE, INC. Files SEC form 10-K, Annual Report
07:07AM  Q4 2015 Trovagene Inc Earnings Release - 4:00 pm ET
Mar-08-16 08:15AM  Presentation at the Molecular Medicine Tri-Conference to Highlight Clinical Performance of Trovagene's Precision Cancer Monitoring Platform PR Newswire +5.85%
Mar-07-16 11:00AM  What's in Store for TrovaGene (TROV) in Q4 Earnings?
Mar-02-16 01:10PM  TrovaGene (TROV) Inks Deal with Multiplan; Shares Rally
Mar-01-16 08:17AM  TROVAGENE, INC. Files SEC form 8-K, Other Events +11.84%
08:15AM  Trovagene Enters Into Preferred Provider Agreement with Multiplan, Inc. PR Newswire
Feb-29-16 08:25AM  TROVAGENE, INC. Files SEC form 8-K, Other Events
08:15AM  Trovagene Schedules Release of Fourth Quarter and Year End 2015 Financial Results and Investor Conference Call PR Newswire
Feb-24-16 08:18AM  TROVAGENE, INC. Files SEC form 8-K, Other Events +5.97%
08:15AM  Trovagene Enters into Preferred Provider Agreement with Three Rivers Provider Network PR Newswire
Feb-23-16 04:10PM  TrovaGene (TROV) Up on Fortified Provider Network Deal +6.11%
Feb-22-16 08:17AM  TROVAGENE, INC. Files SEC form 8-K, Other Events +5.29%
08:15AM  Trovagene Enters into Preferred Provider Agreement with Fortified Provider Network PR Newswire
Feb-08-16 01:03PM  TROVAGENE, INC. Files SEC form 8-K, Other Events -5.19%
08:10AM  Trovagene to Present at Leerink Partners 5th Annual Global Healthcare Conference PR Newswire
Feb-01-16 01:14PM  Heres Why TrovaGene (TROV) Stock is Soaring Today at TheStreet +15.11%
12:58PM  Why TrovaGene (TROV) Stock is Surging Today
11:15AM  Could This Be the Turning Point for TrovaGene? at 24/7 Wall St.
10:31AM  Here's Why Shares Of TrovaGene Are Surging
06:29AM  TROVAGENE, INC. Files SEC form 8-K, Other Events
03:29AM  Trovagene Enters into Agreement with FedMed, Inc. and Significantly Expands Patient Access to Its Precision Cancer Monitoring Platform at noodls
03:00AM  Trovagene Enters into Agreement with FedMed, Inc. and Significantly Expands Patient Access to Its Precision Cancer Monitoring Platform PR Newswire
Jan-21-16 04:27PM  Why Is Trovagene Inc. (TROV) Stock Soaring Today? +69.85%
02:28PM  Trovagene (TROV) Stock Soars on America's Choice Provider Network Partnership at TheStreet
01:01PM  Heres Whats Pushing These 5 Stocks Higher Today at Insider Monkey
11:34AM  4 Nasdaq Stocks That Are Trading Higher Today Accesswire
10:38AM  TROVAGENE, INC. Files SEC form 8-K, Other Events
08:15AM  Trovagene Announces Agreement with America's Choice Provider Network to Offer Patients Access to its ctDNA Precision Cancer Monitoring Platform PR Newswire
Jan-13-16 04:21PM  TROVAGENE, INC. Files SEC form 8-K/A, Other Events
Jan-11-16 08:43AM  TROVAGENE, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -14.89%
Jan-07-16 04:17PM  TROVAGENE, INC. Files SEC form 8-K, Change in Directors or Principal Officers -7.71%
Dec-24-15 10:28AM  TrovaGene, Inc. Earnings Analysis: Q3, 2015 By the Numbers
07:50AM  How it All Plays Out - Analyst Notes on Bazaarvoice, Straight Path Communications, Trovagene and Eldorado Resorts Accesswire
Dec-23-15 04:24PM  TROVAGENE, INC. Files SEC form 8-K, Other Events
Dec-17-15 02:45PM  TrovaGene (TROV) Receives New Patent for PCM Technology -5.17%
Dec-16-15 04:06PM  TROVAGENE, INC. Files SEC form 8-K, Other Events +5.84%
08:15AM  Trovagene Announces Patent Issuance, Broadening its Precision Cancer Monitoring IP Portfolio PR Newswire
Dec-15-15 04:17PM  TROVAGENE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Amendment or Waiver to Code of Ethics +8.73%
Dec-11-15 11:51AM  Funds Hold These 4 Favorably-Ranked Stocks: Do You?
08:32AM  How TrovaGene (TROV) Stock Stands Out in a Strong Industry
Dec-09-15 04:05PM  Trovagene Adjourns Special Meeting of Stockholders to December 23, 2015 PR Newswire -5.39%
Nov-30-15 09:39AM  What Hedge Funds Think About TriplePoint Venture Growth BDC Corp (TPVG) at Insider Monkey -6.92%
Nov-27-15 08:05AM  Can The Uptrend Continue for TrovaGene (TROV)?
Nov-25-15 09:16AM  TROVAGENE, INC. Files SEC form 8-K, Other Events +6.73%
08:15AM  Trovagene to Present at 27th Annual Piper Jaffray Healthcare Conference and Attend Evercore ISI Investor Conference PR Newswire
Nov-20-15 08:30AM  A Look Inside the Chart, Technical Insights - Research on Tilly's, Geospace Technologies, Synthetic Biologics and TrovaGene Accesswire
Nov-19-15 04:17PM  TROVAGENE, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Nov-16-15 08:05AM  Trovagene to Present at Upcoming Healthcare Conferences PR Newswire
07:58AM  TROVAGENE, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Nov-10-15 09:50AM  TrovaGene Rallies despite Wider-than-Expected Q3 Loss +16.30%
12:22AM  Edited Transcript of TROV earnings conference call or presentation 9-Nov-15 10:00pm GMT
Nov-09-15 06:35PM  Trovagene reports 3Q loss
04:22PM  TROVAGENE, INC. Files SEC form 8-K, Results of Operations and Financial Condition
Trovagene, Inc., a molecular diagnostic company, focuses on the development and commercialization of proprietary urine-based cell-free molecular diagnostic technology for use in disease detection and monitoring across various medical disciplines. The company intends to enhance the treatment outcomes for cancer patients through its proprietary technology to detect and quantitatively monitor cell-free DNA using urine or blood samples. It offers Precision Cancer Monitoring (PCM) platform, a cell-free molecular diagnostic platform that provides cancer monitoring by tracking and quantifying levels of cell-free DNA from either urine or blood samples, as well as intends to provide clinical information beyond the current standard of care. The company also provides assays for the BRAF, KRAS, and epidermal growth factor receptor oncogenes; and engages in developing mutation coverage for other cancers, such as lung cancer, as well as targeting clinically validated gene rearrangements, such as ALK, RET, and ROS. In addition, it offers laboratory developed tests for oncogene mutations to end users through a sales and marketing organization. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. Trovagene, Inc. was founded in 1999 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ZANIBONI STEVEFormer CFOApr 21Option Exercise3.6575,639275,86696,968Apr 22 04:05 PM
Tennant StanleyDirectorAug 12Buy6.0610,00060,600192,762Aug 12 04:50 PM
SCHUH ANTONIUSCEOAug 12Buy5.4520,000109,00020,000Aug 12 04:35 PM
BRIDGER MANAGEMENT, LLC10% OwnerJul 17Buy8.75140,0001,225,0003,290,587Jul 21 05:27 PM